Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Gross Profit (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Gross Profit over the past 3 years, most recently at $4.3 million for Q4 2025.

  • Quarterly results put Gross Profit at $4.3 million for Q4 2025, up 209.65% from a year ago — trailing twelve months through Dec 2025 was $6.5 million (up 177.67% YoY), and the annual figure for FY2025 was $6.5 million, up 177.67%.
  • Gross Profit for Q4 2025 was $4.3 million at Tonix Pharmaceuticals Holding, up from $1.9 million in the prior quarter.
  • Over the last five years, Gross Profit for TNXP hit a ceiling of $4.3 million in Q4 2025 and a floor of -$1.3 million in Q2 2025.
  • Median Gross Profit over the past 3 years was $1.4 million (2023), compared with a mean of $1.2 million.
  • Biggest five-year swings in Gross Profit: dropped 21.55% in 2024 and later surged 209.65% in 2025.
  • Tonix Pharmaceuticals Holding's Gross Profit stood at $1.4 million in 2023, then dropped by 0.92% to $1.4 million in 2024, then surged by 209.65% to $4.3 million in 2025.
  • The last three reported values for Gross Profit were $4.3 million (Q4 2025), $1.9 million (Q3 2025), and -$1.3 million (Q2 2025) per Business Quant data.